company background image

Coherus BioSciences NasdaqGM:CHRS Stock Report

Last Price


Market Cap







16 Aug, 2022


Company Financials +
CHRS fundamental analysis
Snowflake Score
Future Growth6/6
Past Performance0/6
Financial Health1/6

CHRS Stock Overview

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States.

Coherus BioSciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Coherus BioSciences
Historical stock prices
Current Share PriceUS$13.39
52 Week HighUS$19.32
52 Week LowUS$5.60
1 Month Change68.01%
3 Month Change79.73%
1 Year Change-8.73%
3 Year Change-33.28%
5 Year Change-2.97%
Change since IPO6.19%

Recent News & Updates

Aug 03

Coherus stock soars 14% on FDA nod for Roche Lucentis' interchangeable biosimilar Cimerli

The U.S. Food and Drug Administration (FDA) approved Coherus BioSciences' (NASDAQ:CHRS) Cimerli, a biosimilar interchangeable with Roche's (OTCQX:RHHBY) (OTCQX:RHHBF) eye disorder drug Lucentis, for all five indications. "CIMERLI, the only biosimilar product interchangeable with Lucentis across all five indications, will provide both greater treatment access and choice for patients, payors and providers in the U.S. retinal disease community," said Coherus Chief Commercial Officer Paul Reider. The company said the uses of Cimerli (ranibizumab-eqrn) include: Neovascular (wet) Age-Related Macular Degeneration, Macular Edema following Retinal Vein Occlusion, Diabetic Macular Edema, Diabetic Retinopathy, and Myopic Choroidal Neovascularization. Coherus noted that Cimerli has 1 year of interchangeability exclusivity. Coherus said commercial availability of Cimerli (ranibizumab-eqrn), in both 0.3 mg and 0.5 mg dosages, is planned for early October 2022. The company noted that the approval was backed by data from clinical programs, including the COLUMBUS-AMD study. CHRS +13.67% to $11.39 premarket Aug. 3.

Jul 06

Coherus, Shanghai Junshi refiling for toripalimab gets FDA review in rare head/neck cancer

The U.S. Food and Drug Administration (FDA) accepted for review Coherus BioSciences (NASDAQ:CHRS) and Shanghai Junshi Biosciences' (OTCPK:SHJBF) resubmitted application seeking approval of toripalimab to treat a rare type of head and neck cancer. The companies' biologics license application (BLA) is seeking approval of toripalimab in combination with gemcitabine and cisplatin as first-line therapy for patients with advanced recurrent or metastatic nasopharyngeal carcinoma (NPC) and for toripalimab monotherapy as a second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy. NPC originates in the nasopharynx, which is located behind the nose and above the back of the throat. The FDA is expected to take a decision on the BLA by Dec. 23. "We collaborated closely with our partner, Junshi Biosciences, to complete the quality process changes requested by the FDA and facilitate the rapid resubmission of the toripalimab BLA,” said Theresa LaVallee, chief development officer, Coherus (CHRS). Coherus (CHRS) plans to launch toripalimab in the U.S. in Q1 2023, if approved.

Shareholder Returns

CHRSUS BiotechsUS Market

Return vs Industry: CHRS exceeded the US Biotechs industry which returned -19.6% over the past year.

Return vs Market: CHRS matched the US Market which returned -9.6% over the past year.

Price Volatility

Is CHRS's price volatile compared to industry and market?
CHRS volatility
CHRS Average Weekly Movement12.0%
Biotechs Industry Average Movement12.5%
Market Average Movement7.6%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: CHRS is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: CHRS's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

2010368Denny Lanfear

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis.

Coherus BioSciences, Inc. Fundamentals Summary

How do Coherus BioSciences's earnings and revenue compare to its market cap?
CHRS fundamental statistics
Market CapUS$1.04b
Earnings (TTM)-US$230.49m
Revenue (TTM)US$276.14m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CHRS income statement (TTM)
Cost of RevenueUS$72.72m
Gross ProfitUS$203.42m
Other ExpensesUS$433.91m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)-2.97
Gross Margin73.67%
Net Profit Margin-83.47%
Debt/Equity Ratio-1,860.3%

How did CHRS perform over the long term?

See historical performance and comparison